Dr. Barry Dworkin

Researchers careful to state that the long-term outcome/efficacy of the immune response to the Oxford vaccine will be known after the Phase 3 arm of the trial. Great science but verification required.

Medical Mythbusting Commentary for July 21, 2020

Source:
Coronavirus: Oxford vaccine triggers immune response

Reference:

Safety and immunogenicity of the ChAdOx1 nCoV-19
vaccine against SARS-CoV-2: a preliminary report of
a phase 1/2, single-blind, randomised controlled trial

Related posts:

  1. Purposefully infecting vaccine-study volunteers with coronavirus to speed up the development and approval process is unethical and fraught with the law of unintended consequences.
  2. Israeli real-world Pfizer vaccine study reports infection rates dropped by 33% in treatment group of 200K people >60 y.o vs 200K controls after 21 days, less than predicted by proponents of delaying 2nd dose. Stay on schedule until proven otherwise.
  3. In vitro studies reported in NEJM show that Pfizer/Moderna vaccines were still able to neutralize variant B.1.351 from South Africa despite reduction in neutralizing antibodies. Authors’ opinion is that vaccine remains efficacious. More to follow.
  4. Ontario study reports that one dose is good but two doses are better against variants. Keep on keeping on. #vaccineswork